Millennium Management LLC Acquires 168,072 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Millennium Management LLC grew its stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 73.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 398,451 shares of the company's stock after purchasing an additional 168,072 shares during the period. Millennium Management LLC owned approximately 0.30% of Centessa Pharmaceuticals worth $6,674,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in the stock. Janus Henderson Group PLC lifted its holdings in Centessa Pharmaceuticals by 279.2% in the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock valued at $82,218,000 after acquiring an additional 3,614,623 shares during the last quarter. Foresite Capital Management VI LLC acquired a new position in Centessa Pharmaceuticals in the fourth quarter valued at approximately $20,994,000. Adage Capital Partners GP L.L.C. lifted its holdings in Centessa Pharmaceuticals by 22.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock valued at $85,744,000 after acquiring an additional 924,027 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Centessa Pharmaceuticals by 14.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock worth $89,854,000 after purchasing an additional 685,371 shares in the last quarter. Finally, Farallon Capital Management LLC lifted its stake in Centessa Pharmaceuticals by 24.3% during the fourth quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company's stock worth $58,603,000 after purchasing an additional 684,391 shares in the last quarter. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider David M. Chao sold 7,000 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $17.17, for a total transaction of $120,190.00. Following the transaction, the insider now owns 225,007 shares in the company, valued at approximately $3,863,370.19. This trade represents a 3.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Saurabh Saha sold 55,000 shares of the firm's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $16.69, for a total transaction of $917,950.00. Following the transaction, the chief executive officer now owns 276,017 shares in the company, valued at $4,606,723.73. This represents a 16.62% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 175,398 shares of company stock valued at $2,551,442. Company insiders own 7.09% of the company's stock.

Centessa Pharmaceuticals Stock Performance

CNTA traded up $0.07 on Friday, hitting $13.14. 751,590 shares of the company's stock were exchanged, compared to its average volume of 660,764. The stock has a fifty day moving average of $12.73 and a two-hundred day moving average of $15.34. Centessa Pharmaceuticals plc has a twelve month low of $7.90 and a twelve month high of $19.09. The firm has a market cap of $1.75 billion, a PE ratio of -8.59 and a beta of 1.53. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.15. On average, research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CNTA has been the topic of several recent analyst reports. Oppenheimer started coverage on Centessa Pharmaceuticals in a report on Thursday, May 8th. They issued an "outperform" rating and a $6.00 target price on the stock. Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Wall Street Zen raised Centessa Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Piper Sandler began coverage on Centessa Pharmaceuticals in a report on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective on the stock. Finally, Guggenheim reiterated a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $27.89.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.